Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Foghorn Therapeutics
Biotech
Foghorn lays off 40% of employees as Lilly collab collapses
Foghorn Therapeutics is laying off 40% of its workforce after a long-running collaboration with Eli Lilly collapsed over disappointing phase 1 data.
James Waldron
Oct 1, 2026 8:36am
Merck discontinues development of 2 late-stage cancer assets
Dec 16, 2024 5:39pm
Foghorn drops sole wholly owned clinical asset after AML failure
Dec 16, 2024 7:48am
BMS vet answers Foghorn’s call for CBO—Chutes & Ladders
Sep 6, 2024 8:30am
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Foghorn sinks eye tumor plans after glimpsing phase 1 data
Jun 28, 2023 8:45am
